Business
BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th
BioMarin Leadership and External Medical Experts to Discuss 7 Product Candidates in Clinical Development as well as ROCTAVIAN and VOXZOGO New Indication
About this update from Biomarin Pharmaceutical Inc.
[{"type":"text","content":"BioMarin Leadership and External Medical Experts to Discuss 7 Product Candidates in Clinical Development as well as ROCTAVIAN and VOXZOGO New Indication Opportunities \nR&D Day to be Webcast Beginning at 8:00 a.m. Eastern Time September 12th \nSAN RAFAEL, Calif., Sept. 6, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will host an R&D Day at 8:00 a.m. ET on Tuesday, September 12, 2023. BioMarin management and external experts will provide an update to the investment community on the company's development portfolio.\n\n \n \n \n \n \n \n\n \nKey topics to be discussed at BioMarin's R&D Day:\nPipeline Programs:\nBMN 255 for hyperoxaluria in nonalcoholic fatty liver disease BMN 349 for alpha-1 antitrypsin deficiencyBMN 331 for hereditary angioedema BMN 351 for Duchenne muscular dystrophy BMN 293 for myosin binding protein C3 hypertrophic cardiomyopathy New Candidate BMN 365 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathyNew Candidate BMN 355 for long-QT syndrome types 2 and 3ROCTAVIAN panel discussion on severe hemophilia A and new indications: \nProfessor Johnny Mahlangu, MBBCh, MMed, FCPath – Director Haemophilia Comprehensive Care, Charlotte Maxeke Johannesburg Academic Hospital, Professor of Haematology, University of the Witwatersrand and National Health Laboratory Service, JohannesburgProfessor Amit Nathwani, MBChB, FRCP, RCPath, Ph.D.- Director of the Katharine Dormandy Hemophilia Centre, Royal Free Hospital, LondonGuy Young, M.D. – Director, Hemostasis and Thrombosis Center and Clinical Coagulation Laboratory, Children's Hospital; Professor of Pediatrics, University of Southern California's Keck School of Medicine, Los AngelesVOXZOGO panel discussion on achondroplasia and new indications: \nAndrew Dauber, M.D. - Chief of Endocrinology, Children's National Hospital, Washington, D.C.Melita Irving, M.B.B.S. - Consultant in Clinical Genetics, Guy's and St. Thomas' NHS Foundation Trust, Evelina Children's Hospital, London, UKBradley Miller, M.D., Ph.D. - Director, Division of Endocrinology, M Health Fairview Masonic Children's Hospital; Professor, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MinnesotaLive Audio Webcast\nAn audio webcast of the presentations will be available live. ...